Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Scientists said on Wednesday many Tibetans possess a rare variant of a gene involved in carrying oxygen in the blood that they likely inherited from an enigmatic group of extinct humans who interbred with our species tens of thousands of years ago. It enables Tibetans to function well in low oxygen levels at elevations upwards of 15,000 feet (4,500 meters) like the vast high plateau of southwestern China. People without this variant would be apt to develop thick blood, leading to high blood pressure, heart attacks, strokes, low-birth-weight babies and higher infant mortality. This version of the EPAS1 gene is nearly identical to one found in Denisovans, a lineage related to Neanderthals - but is very different from other people today. Denisovans are known from a single finger bone and two teeth found in a Siberian cave. DNA testing on the 41,000-year-old bone indicated Denisovans were distinct from our species and Neanderthals. “Our finding may suggest that the exchange of genes through mating with extinct species may be more important in human evolution than previously thought,” said Rasmus Nielsen, a computational biology professor at the University of California, Berkeley and the University of Copenhagen, whose study appears in the journal Nature. Our genome contains residual genetic fragments from other organisms like viruses as well as species like Neanderthals with which early modern humans interbred. The researchers called their study the first to show that a gene from an archaic human species has helped modern humans adjust to different living conditions. “Such exchange of genes with other species may in fact have helped humans adapt to new environments encountered as they spread out of Africa and into the rest of the world,” said  Nielsen. Asan Ciren, a researcher with China’s BGI genomics center, added, “The genetic relationship or blood relationship between modern humans and archaic hominins is a hot topic of the current paleoanthropology.”  The researchers said early modern humans trekking out of Africa interbred with Denisovans in Eurasia en route to China. Their descendants harbor a tiny percentage of Denisovan DNA. Genetic studies show nearly 90 percent of Tibetans have the high-altitude gene variant, along with a small percentage of Han Chinese, who share a common ancestor with Tibetans. It is seen in no other people. The researchers conducted genetic studies on 40 Tibetans and 40 Han Chinese and performed a statistical analysis showing that the gene variant almost certainly was inherited from the Denisovans. The gene regulates production of hemoglobin, a protein in red blood cells that carries oxygen. It is turned on when blood oxygen levels drop, stimulating more hemoglobin production. At elevations above 13,000 feet (4,000 meters), the common form of the gene boosts hemoglobin and red blood cell production, causing dangerous side effects. The Tibetans’ variant increases hemoglobin and red blood cell levels only modestly, sparing them these effects.
[EX A]: Gene from extinct human species fortifies high-altitude Tibetans.

[EX Q]: "At a minimum, the reporter could have found out how much the master used in the study typically charges and how much the DVD costs. Still, unlike most of the stories, this reporter did write, ""Dr. Shmerling said that though tai chi is inexpensive compared with other treatments, some patients would reject such an alternative therapy."" The story presents the evidence in relative terms. It would have been nice to see the absolute numbers. Still, it’s easy to calculate roughly what one third of 33 would be and one sixth would be. Essentially about 11 people stopped taking drugs after tai chi, and 5 or 6 stopped using other therapies. That’s not a huge difference, but, because there was any improvement, the researchers and the journal were understandably curious and hoping the study might spark more research. A big point of the story is that tai chi would be a much less onerous therapy with no harmful side effects. It is difficult to imagine that twice-weekly tai chi, like any other form of moderate exercise, would be harmful, but, at a minimum, the story could have reported upon the study’s adverse events registry. The journal article on which the story is based clearly discussed this. The story makes it clear early that the study is small and that more research would be needed in order to recommend tai chi as a therapy. There is no disease mongering and the description of the syndrome is the best of the five stories we reviewed. Most of the quotes in the story are from people not affiliated with the study. The story talks about how the study compared different alternatives, and it mentions, at least in passing, several other therapies. The story makes it clear that there are multiple versions of tai chi. It could have been more clear about how widely available it might be, especially in sparsely populated areas. The story says, ""Recent studies have suggested that tai chi, with its slow exercises, breathing and meditation, could benefit patients with other chronic conditions, including arthritis. But not all of these reports have been conclusive, and tai chi is hard to study because there are many styles and approaches."" This is all important context, succinctly presented. This story shows that you can pull together a lot of information and still keep the story tight. The story is very well reported and goes well beyond the original study, the editorial and any supporting materials. We were unable to locate a press release about the study."
[EX A]: Tai Chi Reported to Ease Fibromyalgia

[EX Q]: The accord announced on Thursday by the U.S. Department of Justice resolves allegations that CareFusion violated the federal False Claims Act by paying $11.6 million to a doctor to promote its ChloraPrep product to healthcare providers. That doctor, Charles Denham, received the kickbacks while serving as co-chair of the safe practices committee of the nonprofit National Quality Forum, which makes recommendations on healthcare practices, the Justice Department said. “Corrupting the standard-setting process through kickbacks can affect the healthcare treatment choices that doctors and hospitals may make for patients,” Stuart Delery, assistant attorney general for the Justice Department’s civil division, said in a statement. The lawsuit also claimed that CareFusion promoted ChloraPrep from September 2009 through August 2011 for unapproved uses. The U.S. Food and Drug Administration had approved ChloraPrep to prepare patients’ skin for surgery or injections. CareFusion said on Thursday that it set aside funds for the settlement in the first quarter of 2013. Chief Executive Officer Kieran Gallahue said the San Diego-based company is pleased to settle, and has made “significant investments” to improve its quality and compliance practices, including in sales and marketing. Denham could not immediately be reached for comment. The accord resolved a whistleblower lawsuit first brought in September 2010 by Cynthia Kirk, a former vice president of regulatory affairs at a CareFusion infection prevention unit. She will receive $3.26 million through the settlement, which along with the lawsuit was unsealed this week by the federal court in Kansas City, Kansas. In afternoon trading, CareFusion shares were up 81 cents at $41.12. The case is U.S. ex rel. Kirk v. CareFusion Corp et al, U.S. District Court, District of Kansas, No. 10-02492.
[EX A]:
CareFusion to pay $40 million to settle U.S. kickbacks lawsuit.